Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.

The Phase I trial will involve 70 healthy volunteers and comprises a Single Ascending Dose and a Multiple Ascending Dose part. It aims to assess the safety and tolerability profile and the pharmacokinetic characteristics of the investigational medicine. In addition, the trial will generate initial insights into the compound's pharmacology through a cold-pressor test.

"Inhibition of NaV 1.8 offers an exciting opportunity to provide patients with urgently needed non-opioid pain therapies," says Uli Brödl, Chief Scientific Officer, Grünenthal. "While we have seen the first medicine targeting NaV 1.8 receive FDA approval last year, we are committed to driving further innovation in this field where advanced assets may provide enhanced patient outcomes by blocking NaV 1.8 more comprehensively."

About voltage-gated sodium channels (NaV)

There are a total of nine different NaV channels in the human body. The NaV 1.8 channel is a clinically and genetically validated pain target, as the channel plays a significant role in triggering excitatory signals in nociceptive neurons, which the human brain perceives as pain. Blocking the NaV 1.8 channel to suppress or prevent its excitatory signalling will provide a significant analgesic effect across a range of chronic and acute pain conditions.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of EUR1.8 billion.

More information:https://www.grunenthal.com

Follow us on: LinkedIn: Grunenthal Group (https://www.linkedin.com/company/gruenenthal?originalSubdomain=de)

Instagram: grunenthal (https://www.instagram.com/grunenthal/?hl=de)

Click here for our Grünenthal Report 2024/2025 (https://grunenthal-annualreport24.corporate-report.net/#0)

Contact:
Maren Thurow, Head Global Communications at Grünenthal
maren.thurow@grunenthal.com

Logo

Tags

More Like This

Oblique Therapeutics announces that NaV 1.8 project is advancing to next stage

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Fermion announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA

GRÜNENTHAL TAKES FULL OWNERSHIP OF GRÜNENTHAL MEDS, THE JOINT VENTURE ESTABLISHED WITH KYOWA KIRIN FOR ITS ESTABLISHED MEDICINES BRANDS

GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain